These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 17667747)
41. Positron emission tomography scanning in malignant melanoma. Tyler DS; Onaitis M; Kherani A; Hata A; Nicholson E; Keogan M; Fisher S; Coleman E; Seigler HF Cancer; 2000 Sep; 89(5):1019-25. PubMed ID: 10964332 [TBL] [Abstract][Full Text] [Related]
42. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581 [TBL] [Abstract][Full Text] [Related]
43. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Kurli M; Reddy S; Tena LB; Pavlick AC; Finger PT Am J Ophthalmol; 2005 Aug; 140(2):193-9. PubMed ID: 15992753 [TBL] [Abstract][Full Text] [Related]
44. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274 [TBL] [Abstract][Full Text] [Related]
45. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Swetter SM; Carroll LA; Johnson DL; Segall GM Ann Surg Oncol; 2002 Aug; 9(7):646-53. PubMed ID: 12167578 [TBL] [Abstract][Full Text] [Related]
46. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370 [TBL] [Abstract][Full Text] [Related]
47. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. Bronstein Y; Ng CS; Rohren E; Ross MI; Lee JE; Cormier J; Johnson VE; Hwu WJ AJR Am J Roentgenol; 2012 Apr; 198(4):902-8. PubMed ID: 22451559 [TBL] [Abstract][Full Text] [Related]
48. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. Basu S; Alavi A Clin Nucl Med; 2007 May; 32(5):388-9. PubMed ID: 17452870 [No Abstract] [Full Text] [Related]
49. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077 [TBL] [Abstract][Full Text] [Related]
50. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. Tatsumi M; Miller JH; Wahl RL J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332 [TBL] [Abstract][Full Text] [Related]
51. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. Abbott RA; Acland KM; Harries M; O'Doherty M Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913 [TBL] [Abstract][Full Text] [Related]
52. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Mottaghy FM; Sunderkötter C; Schubert R; Wohlfart P; Blumstein NM; Neumaier B; Glatting G; Ozdemir C; Buck AK; Scharffetter-Kochanek K; Reske SN Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1355-64. PubMed ID: 17295038 [TBL] [Abstract][Full Text] [Related]
53. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315 [TBL] [Abstract][Full Text] [Related]
54. [The role of PET scan in the diagnosis of malignant melanoma]. Hunyadi J; Szakáll S; Gilde K; Bégány A; Esik O; Trón L; Galuska L; Ocsai H; Török L Orv Hetil; 2002 May; 143(21 Suppl 3):1272-5. PubMed ID: 12077913 [TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575 [TBL] [Abstract][Full Text] [Related]
56. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095 [TBL] [Abstract][Full Text] [Related]
57. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034 [TBL] [Abstract][Full Text] [Related]
58. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Nakamoto Y; Osman M; Wahl RL Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709 [TBL] [Abstract][Full Text] [Related]
59. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. Schöder H; Carlson DL; Kraus DH; Stambuk HE; Gönen M; Erdi YE; Yeung HW; Huvos AG; Shah JP; Larson SM; Wong RJ J Nucl Med; 2006 May; 47(5):755-62. PubMed ID: 16644744 [TBL] [Abstract][Full Text] [Related]
60. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs? Löffler M; Weckesser M; Franzius Ch; Nashan D; Schober O Nuklearmedizin; 2003 Aug; 42(4):167-72. PubMed ID: 12937695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]